The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Revenue in Q2 2026 increased 48% to $23.0 billion
driven primarily by Mounjaro and Zepbound volume.Q2 2026 EPS increased by 26% to $7.94
on a reported basis and increased by 33% … [+37810 chars]
Discussion (0)
No comments yet. Be the first to share your thoughts!
Join the Conversation
You need to be logged in to leave a comment.
Sign In Create Account